Russian Military Medical Academy ReportsRussian Military Medical Academy ReportsИзвестия Российской Военно-медицинской академии2713-23152713-2323Eco-Vector70671810.17816/rmmar706718ReviewsНаучные обзорыThe effect of hypoglycemic therapy on the course of the wound process in patients with type 2 diabetes and/or obesity.Влияние сахароснижающей терапии на течение раневого процесса у пациентов с сахарным диабетом 2 типа и/или ожирением.https://orcid.org/0000-0002-2257-55569736-2989GurbaMikhail O.ГурбаМихаил Олегович
Russian Federation

Адъюнкт (отдела научной работы и подготовки научно-педагогических кадров)

mikhail.gurba@yandex.ruhttps://orcid.org/0000-0003-1851-0941558041841004531-6011SalukhovVladimir V.СалуховВладимир Владимирович
Russian Federation

Chief of the 1st Department of Advanced Medical Studies n.a. acad. N. S. Molchanov, MD, PhD, professor

Начальник 1 кафедры (терапии усовершенствования врачей) им. акад. Н. С. Молчанова, д.м.н., профессор

vv@salukhov.ruMilitary Medical Academy n.a. S.M. KirovФГБВОУ ВО "Военно-медицинская академия им. С.М. Кирова" МО РФMilitary Medical Academy named after S.M. KirovФГБВОУ ВО «Военно-медицинская академия им. С.М. Кирова» МО РФ160720262504202607062026Copyright ©; , Eco-VectorCopyright ©; , Эко-ВекторEco-VectorЭко-Векторhttps://creativecommons.org/licenses/by-nc-nd/4.0https://journals.eco-vector.com/RMMArep/article/view/706718

This review analyzes publications on the effect of hypoglycemic drugs on the wound healing process. Diabetes mellitus andobesity have a negative effect on wound repair processes, slowing down and disrupting their progression, which leads to the appearance of chronic non-healing wounds. The current understanding of the use of antidiabetic drugs is currently changingsignificantly. In addition to the main hypoglycemic effect, it is of interest to study the pleiotropic effects of both metformin, which has been used in clinical practice for more than 60 years, and more modern drugs from the SGLT-2 inhibitors, DPP-4 inhibitors groups, sulfonylureas, meglitinides, GLP-1 receptor agonists and the double GLP-1/GIP agonist tirzepatide. The anti-inflammatoryand reparative effects of these drugs are being investigated, the implementation of which in practice may open up new prospects inthe treatment of wounds. There have been accumulated studies in which the use of drugs of these groups demonstrated a positiveeffect on regenerative processes both in vitro and reduced the time and improved the quality of wound healing in vivo. Promisingareas of further research are determined by the authors to evaluate the effectiveness of using incretin-type drugs and topical forms of hypoglycemic drugs as wound healing agents, including for acute wounds not associated with metabolic disorders, as well as the safety of their use in humans, including with their neutral metabolic status.

В данном обзоре проводится анализ публикаций, посвященных влиянию сахароснижающих препаратов на процесс заживления ран. Сахарный диабет и ожирение оказывают отрицательное влияние на процессы раневой репарации, замедляя и нарушая их стадийность, что приводит к возникновению хронических незаживающих ран. Современные представления об использовании противодиабетических препаратов в настоящее время существенно расширяются. Представляет интерес, помимо основного гипогликемического эффекта, изучение плейотропных эффектов как используемого в клинической практике в течение более чем 60 лет метформина, так и более современных препаратов из групп иНГЛТ-2, иДПП-4, препаратов сульфонилмочевины, меглитинидов, агонистов рецепторов ГПП-1 и двойного агониста ГПП-1 и ГИП тирзепатида. Исследуются противовоспалительный и репаративный эффекты данных лекарств, реализация которых в практике может открыть новые перспективы в лечении ран. Накоплены исследования, в которых использование препаратов данных групп демонстрировало положительное влияние на регенераторные процессы как in vitro, так и уменьшало сроки и повышало качество заживления ран in vivo. Перспективными направлениями дальнейших исследований авторами определяются оценка эффективности использования в качестве ранозаживляющих средств препаратов инкретинового ряда и топических форм сахароснижающих препаратов, в том числе, при острых ранах, не связанных с нарушениями метаболизма, а также безопасности их использования у людей, в том числе, при их нейтральном метаболическом статусе.

Reviewhyperglycemiametabolisminflammationwound healingmetforminglucagon-like peptide-1 receptor agonistssulfonylurea compoundsinsulinmeglitinidesdipeptidyl-peptidase IV inhibitorssodium-glucose transporter 2 inhibitorstirzepatideОбзоргипергликемияметаболизмвоспалениезаживление ранметформинагонисты рецептора глюкагоноподобного пептида-1производные сульфонилмочевиныинсулинмеглитинидыдипептидил-пептидазы-IV ингибиторыингибиторы натрий-глюкозного контранспортера 2 типатирзепатидKaras RA, Alexeree S, Elsayed H, Attia YA. Assessment of wound healing activity in diabetic mice treated with a novel therapeutic combination of selenium nanoparticles and platelets rich plasma. Sci Rep. 2024;14(1):5346. doi:10.1038/s41598-024-54064-2Shojaeian A. Harnessing the Power of Non-diabetic Benefits of Metformin Derived from Galega officinalis: Focus on Wound Healing. J Wound Manag Res. 2024;20(3):212-218. doi:10.22467/jwmr.2024.02957Reinke JM, Sorg H. Wound Repair and Regeneration. Eur Surg Res. 2012;49(1):35-43. doi:10.1159/000339613Wang PH, Huang BS, Horng HC, et al. Wound healing. Journal of the Chinese Medical Association. 2018;81(2):94-101. doi:10.1016/j.jcma.2017.11.002Fernández-Guarino M, Hernández-Bule ML, Bacci S. Cellular and Molecular Processes in Wound Healing. Biomedicines. 2023;11(9):2526. doi:10.3390/biomedicines11092526Jeschke MG, van Baar ME, Choudhry MA, et al. Burn injury. Nat Rev Dis Primers. 2020;6(1):11. doi:10.1038/s41572-020-0145-5Bastard JP, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006;17(1):4-12.Brem H, Tomic-Canic M. Cellular and molecular basis of wound healing in diabetes. J Clin Invest. 2007;117(5):1219-1222. doi:10.1172/JCI32169Brass LF, Bensusan HB. On the role of the collagen carbohydrate residues in the platelet. Collagen interaction. Biochim Biophys Acta. 1976;444(1):43-52. doi:10.1016/0304-4165(76)90222-1Salukhov VV, Asadova LA, Varavin NI. Disordered carbohydrate metabolism and its impact on hemostasis: from hypercoagulation to cardiovascular complications. Russian Medical Inquiry. 2025;9(10):735-742 (in Russ.). doi:10.32364/2587-6821-2025-9-10-6Салухов ВВ, Асадова ЛА, Варавин НИ. Нарушение углеводного обмена и его влияние на гемостаз: от гиперкоагуляции к сердечно-сосудистым осложнениям. РМЖ. Медицинское обозрение. 2025;9(10):735-742. doi:10.32364/2587-6821-2025-9-10-6Greaves J, Pula G. Hyperactivity and Pro-inflammatory Functions of Platelets in Diabetes. Front Biosci (Landmark Ed). 2025;30(1):26190. doi:10.31083/FBL26190Alsharidah AS. Diabetes mellitus and diabetic nephropathy: a review of the literature on hemostatic changes in coagulation and thrombosis. Blood Res. 2022;57(2):101-105. doi:10.5045/br.2022.2021204Kaur R, Kaur M, Singh J. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies. Cardiovasc Diabetol. 2018;17(1):121. doi:10.1186/s12933-018-0763-3Andrade TAM, Masson-Meyers DS, Caetano GF, et al. Skin changes in streptozotocin-induced diabetic rats. Biochem Biophys Res Commun. 2017;490(4):1154-1161. doi:10.1016/j.bbrc.2017.06.166Muniyappa R, Sowers JR. Role of insulin resistance in endothelial dysfunction. Rev Endocr Metab Disord. 2013;14(1):5-12. doi:10.1007/s11154-012-9229-1O’Hara A, Pozin J, Darki A, et al. Glycemic Control and Plasma Levels of Pro-Inflammatory and Pro-Thrombotic Biomarkers in Diabetic Patients Presenting with Acute Pulmonary Embolism. Clin Appl Thromb Hemost. 2023;29:10760296231165058. doi:10.1177/10760296231165058Bybee JD, Rogers DE. The phagocytic activity of polymorphonuclear leukocytes obtained from patients with diabetes mellitus. J Lab Clin Med. 1964;64:1-13Bagdade JD, Root RK, Bulger RJ. Impaired leukocyte function in patients with poorly controlled diabetes. Diabetes. 1974;23(1):9-15. doi:10.2337/diab.23.1.9Jafar N, Edriss H, Nugent K. The Effect of Short-Term Hyperglycemia on the Innate Immune System. Am J Med Sci. 2016;351(2):201-211. doi:10.1016/j.amjms.2015.11.011Mowat A, Baum J. Chemotaxis of polymorphonuclear leukocytes from patients with diabetes mellitus. N Engl J Med. 1971;284(12):621-627. doi:10.1056/NEJM197103252841201Dong H, Sun Y, Nie L, et al. Metabolic memory: mechanisms and diseases. Sig Transduct Target Ther. 2024;9(1):38. doi:10.1038/s41392-024-01755-xHofmann MA, Drury S, Qu W, et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell. 1999;97(7):889-901. doi:10.1016/s0092-8674(00)80801-6Senn JJ, Klover PJ, Nowak IA, Mooney RA. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes. 2002;51(12):3391-3399. doi:10.2337/diabetes.51.12.3391Wetzler C, Kämpfer H, Stallmeyer B, et al. Large and sustained induction of chemokines during impaired wound healing in the genetically diabetic mouse: prolonged persistence of neutrophils and macrophages during the late phase of repair. J Invest Dermatol. 2000;115(2):245-253. doi:10.1046/j.1523-1747.2000.00029.xHotamisligil GS. Inflammation, metaflammation and immunometabolic disorders. Nature. 2017;542(7640):177-185. doi:10.1038/nature21363Aronson D, Rayfield EJ. How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovasc Diabetol. 2002;1:1. doi:10.1186/1475-2840-1-1Zhao M, Wang S, Zuo A, et al. HIF-1α/JMJD1A signaling regulates inflammation and oxidative stress following hyperglycemia and hypoxia-induced vascular cell injury. Cell Mol Biol Lett. 2021;26:40. doi:10.1186/s11658-021-00283-8Lien YH, Stern R, Fu JC, Siegel RC. Inhibition of collagen fibril formation in vitro and subsequent cross-linking by glucose. Science. 1984;225(4669):1489-1491. doi:10.1126/science.6147899O’Sullivan JB, Hanson R, Chan F, Bouchier-Hayes DJ. Tight glycaemic control is a key factor in wound healing enhancement strategies in an experimental diabetes mellitus model. Ir J Med Sci. 2011;180(1):229-236. doi:10.1007/s11845-010-0630-zSpanheimer RG, Umpierrez GE, Stumpf V. Decreased Collagen Production in Diabetic Rats. Diabetes. 1988;37(4):371-376. doi:10.2337/diab.37.4.371Seifter E, Rettura G, Padawer J, et al. Impaired wound healing in streptozotocin diabetes. Prevention by supplemental vitamin A. Ann Surg. 1981;194(1):42-50. doi:10.1097/00000658-198107000-00008Tellechea A, Kafanas A, Leal EC, et al. Increased Skin Inflammation and Blood Vessel Density in Human and Experimental Diabetes. Int J Low Extrem Wounds. 2013;12(1):4-11. doi:10.1177/1534734612474303Burgess JL, Wyant WA, Abdo Abujamra B, et al. Diabetic Wound-Healing Science. Medicina (Kaunas). 2021;57(10):1072. doi:10.3390/medicina57101072Spravchikov N, Sizyakov G, Gartsbein M, et al. Glucose Effects on Skin Keratinocytes: implications for diabetes skin complications. Diabetes. 2001;50(7):1627-1635. doi:10.2337/diabetes.50.7.1627Lerman OZ, Galiano RD, Armour M, et al. Cellular Dysfunction in the Diabetic Fibroblast. Am J Pathol. 2003;162(1):303-312. doi:10.1016/S0002-9440(10)63821-7Bermudez DM, Herdrich BJ, Xu J, et al. Impaired Biomechanical Properties of Diabetic Skin. Am J Pathol. 2011;178(5):2215-2223. doi:10.1016/j.ajpath.2011.01.015Bartling B, Desole M, Rohrbach S, et al. Age‐associated changes of extracellular matrix collagen impair lung cancer cell migration. The FASEB Journal. 2009;23(5):1510-1520. doi:10.1096/fj.08-122648Galstyan GR., Dedov II. Principles of care in diabetic foot patients in Russia. Diabetes mellitus. 2009;12(1):4-7 (in Russ.). doi:10.14341/2072-0351-5411Галстян ГР, Дедов ИИ. Организация помощи больным с синдромом диабетической стопы в Российской Федерации. Сахарный диабет. 2009;12(1):4-7. doi:10.14341/2072-0351-5411Omotosho IA, Shamsuddin N, Zaman Huri H, et al. From Control to Cure: Insights into the Synergy of Glycemic and Antibiotic Management in Modulating the Severity and Outcomes of Diabetic Foot Ulcers. IJMS. 2025;26(14):6909. doi:10.3390/ijms26146909Wang F, Zhang W, Li H, et al. How Effective are Nano-Based Dressings in Diabetic Wound Healing? A Comprehensive Review of Literature. International Journal of Nanomedicine. 2022;17:2097-2119. doi:10.2147/IJN.S361282Komelyagina EY, Antsiferov MB. Clinical features and poutcomes of recalcitrant ulcers in diabetic foot patients: a retrospective cohort study. Endocrinology: News, Opinions, Training. 2020;9(3):21-25. doi:10.33029/2304-9529-2020-9-3-21-25Комелягина ЕЮ, Анциферов МБ. Клиническая характеристика и исходы длительно не заживающих ран у больных с синдромом диабетической стопы: ретроспективное когортное исследование. Эндокринология: новости, мнения, обучение. 2020;9(3):21-25. doi:10.33029/2304-9529-2020-9-3-21-25Salukhov VV, Zelenina TA, Akhmedova KS, et al. The short- and long-term results of therapy of surgical diabetic foot patients. Medical Council. 2024;(16):154-161 (In Russ.). doi:10.21518/ms2024-395Салухов ВВ, Зеленина TА, Ахмедова КС, и соавт. Ближайшие и отдаленные результаты лечения хирургических пациентов с синдромом диабетической стопы. Медицинский совет. 2024;(16):154-161. doi:10.21518/ms2024-395Zemlyanoy AB , Zelenina TA, Rybakov AO, Salukhov VV. A new IORDAN classification for prognosis of the healing of postoperative diabetic foot wounds and subsequent routing of the patients. Medical Bulletin of the Ministry of Internal Affairs. 2025;2025(2):12-19 (In Russ.). doi:10.52341/20738080_2025_135_2_12Земляной AБ, Зеленина TА, Рыбаков AО, Салухов ВВ. Новая классификация «ИОРДАН» для прогноза заживления послеоперационных ран диабетической стопы и последующей маршрутизации пациентов. Медицинский вестник МВД. 2025;2025(2):12-19. doi:10.52341/20738080_2025_135_2_12Salukhov VV, Galstyan GR, Khalimov YS, et al. Practical application of semaglutide: From evidence-based research to expert decisions. Medical Council. 2025;19(6):14-29 (in Russ). doi:10.21518/ms2025-185Салухов ВВ, Галстян ГР, Халимов ЮШ, и др. Практическое применение семаглутида: от доказательных исследований к экспертным решениям. Медицинский совет. 2025;19(6):14-29. doi:10.21518/ms2025-185Dedov II, Shestakova MV, Sukhareva OU, et al. Standards of specialized diabetes care. 12th Edition. 2025. doi:10.14341/DM20255SДедов ИИ, Шестакова МВ, Cухарева ОЮ, и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 12-й выпуск. 2025Romantsova TI, Sych YP. Immunometabolism and metainflammation in obesity. Obesity and metabolism. 2019;16(4):3-17 (in Russ.). doi:10.14341/omet12218Романцова ТИ, Сыч ЮП. Иммунометаболизм и метавоспаление при ожирении. Ожирение и метаболизм. 2019;16(4):3-17. doi:10.14341/omet12218Lin H, Ao H, Guo G, Liu M. The Role and Mechanism of Metformin in Inflammatory Diseases. J Inflamm Res. 2023;16:5545-5564. doi:10.2147/JIR.S436147Vianello E, Beltrami AP, Aleksova A, et al. The Advanced Glycation End-Products (AGE)–Receptor for AGE System (RAGE): An Inflammatory Pathway Linking Obesity and Cardiovascular Diseases. IJMS. 2025;26(8):3707. doi:10.3390/ijms26083707de Jager J, Kooy A, Schalkwijk C, et al. Long-term effects of metformin on endothelial function in type 2 diabetes: a randomized controlled trial. J Intern Med. 2014;275(1):59-70. doi:10.1111/joim.12128Witkowski M, Friebel J, Tabaraie T, et al. Metformin Is Associated with Reduced Tissue Factor Procoagulant Activity in Patients with Poorly Controlled Diabetes. Cardiovasc Drugs Ther. 2021;35(4):809-813. doi:10.1007/s10557-020-07040-7Shi L, Jiang Z, Li J, et al. Metformin Improves Burn Wound Healing by Modulating Microenvironmental Fibroblasts and Macrophages. Cells. 2022;11(24):4094. doi:10.3390/cells11244094Zhang J, Shimozaki K, Hattori S, et al. Metformin lotion promotes scarless skin tissue formation through AMPK activation, TGF-β1 inhibition, and reduced myofibroblast numbers. PLoS One. 2024;19(9):e0311147. doi:10.1371/journal.pone.0311147Maghsoodloo D, Zartab H, Alipour M, et al. Topical metformin in wound healing: a comprehensive systematic review of therapeutic outcomes. Arch Dermatol Res. 2025;317(1):760. doi:10.1007/s00403-025-04277-wHan X, Tao Y, Deng Y, et al. Metformin accelerates wound healing in type 2 diabetic db/db mice. Mol Med Rep. 2017;16(6):8691-8698. doi:10.3892/mmr.2017.7707Pantazopoulos D, Papachristou S, Gouveri E, et al. Metformin: Old Drug, New Therapeutic Potential in the Skin? A Brief Narrative Review. Adv Ther. 2025;42(8):3606-3620. doi:10.1007/s12325-025-03256-xTombulturk FK, Soydas T, Kanigur‐Sultuybek G. Topical metformin accelerates wound healing by promoting collagen synthesis and inhibiting apoptosis in a diabetic wound model. Int Wound J. 2023;21(1):e14345. doi:10.1111/iwj.14345Zhao P, Sui B, Liu N, et al. Anti‐aging pharmacology in cutaneous wound healing: effects of metformin, resveratrol, and rapamycin by local application. Aging Cell. 2017;16(5):1083-1093. doi:10.1111/acel.12635Ochoa-Gonzalez F, Cervantes-Villagrana AR, Fernandez-Ruiz JC, et al. Metformin Induces Cell Cycle Arrest, Reduced Proliferation, Wound Healing Impairment In Vivo and Is Associated to Clinical Outcomes in Diabetic Foot Ulcer Patients. Veves A, ed. PLoS ONE. 2016;11(3):e0150900. doi:10.1371/journal.pone.0150900Salazar JJ, Ennis WJ, Koh TJ. Diabetes medications: Impact on inflammation and wound healing. Journal of Diabetes and its Complications. 2016;30(4):746-752. doi:10.1016/j.jdiacomp.2015.12.017Lin YW, Liu PS, Pook KA, Wei LN. Glyburide and retinoic acid synergize to promote wound healing by anti-inflammation and RIP140 degradation. Sci Rep. 2018;8(1):834. doi:10.1038/s41598-017-18785-xHsu CY, Azzam ER, Merza M, et al. Therapeutic potential of repaglinide-embedded chitosan hydrogel in promoting wound healing. Regen Ther. 2025;29:551-562. doi:10.1016/j.reth.2025.04.021Stuermer EK, Besser M, Terberger N, Koester V, Bachmann HS, Severing AL. Side effects of frequently used oral antidiabetics on wound healing in vitro. Naunyn-Schmiedeberg’s Arch Pharmacol. 2019;392(3):371-380. doi:10.1007/s00210-018-01597-9Vatankhah N, Jahangiri Y, Landry GJ, et al. Effect of systemic insulin treatment on diabetic wound healing. Wound Repair Regeneration. 2017;25(2):288-291. doi:10.1111/wrr.12514Wang R, Gu S, Kim YH, et al. Diabetic Wound Repair: From Mechanism to Therapeutic Opportunities. MedComm. 2025;6(10):e70406. doi:10.1002/mco2.70406Hu S, Gong Y, Zhang H, et al. The effect of topical insulin therapy on diabetic foot ulcers: A systematic review and meta-analysis. J Tissue Viability. 2025;34(3):100932. doi:10.1016/j.jtv.2025.100932Khattab MA, Nabeh OA, Adel S, et al. Topical insulin improves postoperative wound healing in controlled diabetic patients through regulating the expression of E-Cadherin and Ki67: an open-label randomized controlled-trial. Futur J Pharm Sci. 2025;11(1):80. doi:10.1186/s43094-025-00830-6Wang J, Xu J. Effects of Topical Insulin on Wound Healing: A Review of Animal and Human Evidences. Diabetes Metab Syndr Obes. 2020;13:719-727. doi:10.2147/DMSO.S237294Tani S., Takahashi A., Nagao K., Hirayama A. Effect of dipeptidyl peptidase-4 inhibitor, vildagliptin on plasminogen activator inhibitor-1 in patients with diabetes mellitus. Am J Cardiol. 2015;115(4):454-460. doi: 10.1016/j.amjcard.2014.11.044Gao W, Chen D, He H, Jiang N, Chen L, Ran X. Sitagliptin, a DPP-4 Inhibitor, Effectively Promotes the Healing of Diabetic Foot Ulcer: A Randomized Controlled Trial. J Diabetes. 2025;17(9):e70156. doi:10.1111/1753-0407.70156Mamoun LS, Rosenbloom AJ, Gasbeck T, et al. From Glucose to Gauze: A Systematic Review on the Various Wound Healing Properties of DPP‐4 Inhibitors Beyond Glycaemic Control. Wound Repair Regeneration. 2025;33(5):e70090. doi:10.1111/wrr.70090Torrecillas-Baena B, Pulido-Escribano V, Quesada-Gómez JM, et al. Antidiabetic sitagliptin influences tissue regeneration by affecting progenitor cells. Biomedicine & Pharmacotherapy. 2025;189:118279. doi:10.1016/j.biopha.2025.118279Katsuhiro M, Hui Teoh S, Yamashiro H, et al. Effects on Glycemic Control in Impaired Wound Healing in Spontaneously Diabetic Torii (SDT) Fatty Rats. Med Arch. 2018;72(1):4-8. doi:10.5455/medarh.2018.72.4-8Rykova EY, Klimontov VV, Shmakova E, et al. Anti-Inflammatory Effects of SGLT2 Inhibitors: Focus on Macrophages. Int J Mol Sci. 2025;26(4):1670. doi:10.3390/ijms26041670Ullah A, Shen B. Immunomodulatory effects of anti-diabetic therapies: Cytokine and chemokine modulation by metformin, sodium-glucose cotransporter 2 inhibitors, and glucagon-like peptide-1 receptor agonists (2013–2025). European Journal of Medicinal Chemistry. 2025;299:118065. doi:10.1016/j.ejmech.2025.118065Lin YH, Lin CH, Lin YC, et al. Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Hospitalization for Heart Failure and Amputation Rate Compared With Incretin-Based Therapy in Patients With Diabetic Foot Disease: A Nationwide Population-Based Study. Endocrine Practice. 2024;30(5):424-430. doi:10.1016/j.eprac.2024.01.016Roan JN, Cheng HN, Young CC, et al. Exendin-4, a glucagon-like peptide-1 analogue, accelerates diabetic wound healing. J Surg Res. 2017;208:93-103. doi:10.1016/j.jss.2016.09.024Huang H, Wang L, Qian F, et al. Liraglutide via Activation of AMP-Activated Protein Kinase-Hypoxia Inducible Factor-1α-Heme Oxygenase-1 Signaling Promotes Wound Healing by Preventing Endothelial Dysfunction in Diabetic Mice. Front Physiol. 2021;12:660263. doi:10.3389/fphys.2021.660263Nagae K, Uchi H, Morino-Koga S, et al. Glucagon-like peptide-1 analogue liraglutide facilitates wound healing by activating PI3K/Akt pathway in keratinocytes. Diabetes Res Clin Pract. 2018;146:155-161. doi:10.1016/j.diabres.2018.10.013Turhan B, Sağlam S, Yücel MO, et al. The effects of liraglutide and metformin treatment on fracture healing in partially insulinopenic diabetic rats. Front Endocrinol. 2025;16:1703958. doi:10.3389/fendo.2025.1703958Salingaros S, Zhang A, Rohde CH, Spector JA. Active GLP-1 RA Use Is Associated With Lower Rates of Surgical Complications Across Diabetic BMI Cohorts: A Retrospective Analysis of 72,578 Surgical Encounters. Ann Plast Surg. Published online February 13, 2026. doi:10.1097/SAP.0000000000004657Hamedi-Shahraki S, Klisic A, Amirkhizi F, Mercantepe F. Association of the triglyceride-glucose index with inflammatory markers and dysregulation of adipokines in patients with metabolic syndrome. BMC Endocr Disord. Published online January 16, 2026. doi:10.1186/s12902-025-02142-5Wong CK, Drucker DJ. Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits. Journal of Clinical Investigation. 2025;135(21):e194751. doi:10.1172/JCI194751Sugiyama S, Yoshida A, Kurinami N, et al. Once-Weekly Semaglutide Is Associated With Improvement in Vascular Endothelial Function in Patients With Type 2 Diabetes Mellitus: A Retrospective Observational Study. Cureus. 2025;17(12):e99998. doi:10.7759/cureus.99998Anastasiou IA, Tentolouris A, Sarantis P, et al. Semaglutide Enhances Cellular Regeneration in Skin and Retinal Cells In Vitro. Pharmaceutics. 2025;17(9):1115. doi:10.3390/pharmaceutics17091115Lewis JE, Omenge DK, Patterson AR, et al. The impact of semaglutide on wound healing in diabetes related foot ulcer patients: A TriNetX database study. Diabetes & Vascular Disease Research. 2025;22(2):14791641251322909. doi:10.1177/14791641251322909Pastel E, McCulloch LJ, Ward R, et al. GLP-1 analogue-induced weight loss does not improve obesity-induced AT dysfunction. Clin Sci (Lond). 2017;131(5):343-353. doi:10.1042/CS20160803Xia Y, Jin J, Sun Y, et al. Tirzepatide’s role in targeting adipose tissue macrophages to reduce obesity-related inflammation and improve insulin resistance. International Immunopharmacology. 2024;143:113499. doi:10.1016/j.intimp.2024.113499Hegab II, El-Horany HE sayed, Abd-Ellatif RN, et al. Adropin/Tirzepatide Combination Mitigates Cardiac Metabolic Aberrations in a Rat Model of Polycystic Ovarian Syndrome, Implicating the Role of the AKT/GSK3β/NF-κB/NLRP3 Pathway. IJMS. 2024;26(1):1. doi:10.3390/ijms26010001Wilson JM, Lin Y, Luo MJ, et al. The dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis. Diabetes Obesity Metabolism. 2022;24(1):148-153. doi:10.1111/dom.14553Masson W, Lobo M, Nogueira JP, et al. Anti-inflammatory effects of tirzepatide: a systematic review and meta-analysis. Rev Endocr Metab Disord. Published online October 1, 2025. doi:10.1007/s11154-025-09991-4Hu W, Gong W, Yang F, et al. Dual GIP and GLP-1 receptor agonist tirzepatide alleviates hepatic steatosis and modulates gut microbiota and bile acid metabolism in diabetic mice. International Immunopharmacology. 2025;147:113937. doi:10.1016/j.intimp.2024.113937